iBio Study Shows IBIO-610 Enhances Muscle Preservation in Obesity Treatment
News related to:iBio, Inc · 2 min read
SAN DIEGO, Oct. 13, 2026 /CourierPR/ -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic, and cardiopulmonary diseases, has highlighted data from a non-human primate (NHP) study that supports the potential of its Activin E antibody, IBIO-610, in preserving muscle mass when combined with semaglutide, a GLP-1 receptor agonist used to treat obesity. The findings were presented at the European Association for the Study of Diabetes (EASD) Annual Meeting on October 1, 2026.
In an eight-week study involving obese NHPs, the company observed that lean mass made up 6% of the weight lost when IBIO-610 was combined with semaglutide, compared to 22% with semaglutide alone. This indicates that the combination therapy may lead to a more favorable distribution of weight loss, with a greater proportion of fat being lost.
Furthermore, the study showed that when given a single dose of IBIO-610 alongside twice-weekly semaglutide, fat accounted for 93% of the weight lost by the NHPs, compared to 77% for those given semaglutide alone. These results suggest that IBIO-610 can support muscle preservation while promoting fat loss.
IBIO-610 demonstrated a significant reduction in serum levels of active Activin E, with a 97% decrease observed at week 8 following a single intravenous dose. Additionally, the antibody had a 33.2-day half-life in NHPs, which could potentially support twice-yearly dosing in humans.
The company's focus is on translating this biology into a potential new therapeutic option for patients living with obesity and cardiometabolic disease. According to the company's annual report on Form 10-K for the year ended June 30, 2026, iBio is committed to advancing its pipeline of long-acting antibody therapeutics to address significant unmet medical needs.
These findings build on previously reported data from the NHP study, which showed a 97% reduction in serum levels of active Activin E at week 8 following a single intravenous dose. The study also found that IBIO-610 had a 33.2-day half-life in NHPs, with a projected human half-life potentially supporting twice-yearly dosing.